|
Cepivo BCG ima svoje meje in raziskave in razvoj novih cepiv za TB so v teku.<ref name=VacRes2011>{{cite journal|last1=Martín Montañés|first1=C|last2=Gicquel|first2= B|title=New tuberculosis vaccines|journal=Enfermedades infecciosas y microbiologia clinica|date=marec 2011|volume=29 Suppl 1|pages=57-62|pmid=21420568|doi=10.1016/S0213-005X(11)70019-2}}</ref> Številni možni kandidati so trenutno v fazah I in II kliničnih preskusov.<ref name=VacRes2011/> Da bi izboljšali učinkovitost razpoložljivih cepiv, sta na voljo dva pristopa. Pri enem se BCG dodaja cepivo za podenoto, pri drugi strategiji pa se skuša razviti nova in boljša živa cepiva.<ref name=VacRes2011/> [[MVA85A]], primer cepiva s podenoto, ki se trenutno preskuša v Južni Afriki, temelji na gensko spremenjenih [[Vaccinia]] virusih.<ref name=Ibanga_2006>{{cite journal |author=Ibanga H, Brookes R, Hill P, Owiafe P, Fletcher H, Lienhardt C, Hill A, Adegbola R, McShane H |title=Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design |journal=Lancet Infect Dis |volume=6 |issue=8 |pages=522-8 |year=2006 |doi= 10.1016/S1473-3099(06)70552-7| pmid = 16870530}}</ref> Cepiva bodo upajmo igrala pomembno vlogo pri zdravljenju tako latentne kot aktivne bolezni.<ref>{{cite journal|author=Kaufmann SH|title=Future vaccination strategies against tuberculosis: Thinking outside the box|journal=Immunity|year=2010|volume=33|pages=567-77|pmid = 21029966|doi=10.1016/j.immuni.2010.09.015|issue=4}}</ref>
Da bi spodbudili nadaljnji razvoj, raziskovalci in politiki uvajajo nove ekonomske modele za razvoj cepiv, med drugim nagrade, davčne spodbude in vnaprej zagotovljen tržni odvzem.<ref>{{cite journal|author=Webber D, Kremer M|url=http://www.who.int/bulletin/archives/79(8)735.pdf |title=Stimulating Industrial R&D for Neglected Infectious Diseases: Economic Perspectives |journal=Bulletin of the World Health Organization|volume=79|issue=8|year=2001|pages=693-801}}</ref><ref>{{cite journal|author=Barder O, Kremer M, Williams H|url=http://www.bepress.com/ev/vol3/iss3/art1 |title=Advance Market Commitments: A Policy to Stimulate Investment in Vaccines for Neglected Diseases|journal=The Economists' Voice|volume=3|year=2006|issue=3|doi=10.2202/1553-3832.1144}}</ref> Pri razvoju sodelujejo številne skupine, med drugim [[Stop TB Partnership]],<ref>{{cite book|lastauthor=Economic|first= Department of Social Affairs|title=Achieving the global public health agenda : dialogues at the Economic and Social Council|year=2009|publisher=United Nations|location=New York|isbn=978-92-1-104596-3|pages=103|url=http://books.google.ca/books?id=VeF9dv74C4MC&pg=PA103|coauthors=Affairs, Social}}</ref> Južnoafriška iniciativa za cepivo proti tuberkuloz in [[Aeras Global TB Vaccine Foundation]].<ref>{{cite book|last=Jong|first=[edited by] Jane N. Zuckerman, Elaine C.|title=Travelers' vaccines|year=2010|publisher=People's Medical Pub. House|location=Shelton, CT|isbn=978-1-60795-045-5|pages=319|url=http://books.google.ca/books?id=BKRpWFEy66wC&pg=PA319|edition=2nd}}</ref> Podjetje je prejelo več kot 280.000.000 $ (US) od [[Fundacija Bill in Melinda Gates|Fundacije Bill in Melinda Gates]] za razvoj in licenciranje boljšega cepiva proti tuberkulozi, ki naj bi se ga uporabilo v zelo obremenjenih državah.<ref>{{Cite web|last=Bill and Melinda Gates Foundation Announcement|title=Gates Foundation Commits $82.9 Million to Develop New Tuberculosis Vaccines|date=2004-02-12| url=http://www.globalhealth.org/news/article/4134}}</ref><ref>{{Cite web|last=Nightingale|first=Katherine|title=Gates foundation gives US$280 million to fight TB|date=2007-09-19|url=http://www.scidev.net/en/news/gates-foundation-gives-us280-million-to-fight-tb.html}}</ref>
Za tuberkulozo, ki je odporna proti več zdravilom, se raziskuje številna zdravila, med drugim [[bedaquiline]] in [[delamanid]].<ref name=Zumla2012>{{cite journal|lastlast1=Zumla|firstfirst1=A|coauthorslast2=Hafner,|first2= R;|last3= Lienhardt,|first3= C;|last4= Hoelscher,|first4= M;|last5= Nunn,|first5= A|title=Advancing the development of tuberculosis therapy|journal=Nature reviews. Drug discovery|date=20121. Marmarec 12012|volume=11|issue=3|pages=171-2|pmid=22378254|doi=10.1038/nrd3694}}</ref> Bedaquiline je konec 2012 FDA odobrila.<ref>{{cite news|title=J&J Sirturo Wins FDA Approval to Treat Drug-Resistant TB|url=http://www.bloomberg.com/news/2012-12-31/j-j-sirturo-wins-fda-approval-to-treat-drug-resistant-tb.html|accessdate=1. Januaryjanuar 2013|newspaper=Bloombeg|date=Dec 31st,2012}}</ref> Kolikšni sta varnost in učinkovitost teh novih učinkovin še nista čisto jasno, saj rezultati temeljijo na relativno majhnih vzorcih.<ref name=Zumla2012/><ref name="Avorn 2013 1349-1350">{{cite journal|last=Avorn|first=J|title=Approval of a tuberculosis drug based on a paradoxical surrogate measure|journal=JAMA|date=april 2013|volume=309|issue=13|pages=1349-1350|doi=10.1001/jama/2013.623|pmid=23430122}}</ref> Obstoječi podatki pa kažejo, da je pri bolnikih, ki poleg standardnega zdravljenja TB jemljejo bedaquiline, umrljivost petkrat višja kot bolnikih, ki nove droge ne jemljejo.<ref name="US Food and Drug Administration website">{{cite web|last=US Food and Drug Administration.|title=Briefing Package: NDA 204-384: Sirturo|url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-%20InfectiveDrugsAdvisoryCommittee/UCM329258.pdf}}</ref> Posledica so bili članki v strokovni literaturi, ki so odpirali vprašanja glede zdravstvene politike, o tem, zakaj je FDA zdravilo odobrila, in o tem, ali so finančne vezi zdravnikov s podjetjem, ki izdeluje bedaquiline, vplivale na njih ravnanje.<ref name="Avorn 2013 1349-1350"/><ref>{{cite journal|lastlast1=Zuckerman|firstfirst1=Diana|coauthorslast2=Jennifer|first2= Yttri|title=Antibiotics: When science and wishful thinking collide|journal=Health Affairs|date=januar 2013|url=http://healthaffairs.org/blog/2013/01/25/antibiotics-when-science-and-wishful-thinking-collide/}}</ref>
== Druge živali ==
|
